BRPI0416434A - métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina - Google Patents
métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielinaInfo
- Publication number
- BRPI0416434A BRPI0416434A BRPI0416434-2A BRPI0416434A BRPI0416434A BR PI0416434 A BRPI0416434 A BR PI0416434A BR PI0416434 A BRPI0416434 A BR PI0416434A BR PI0416434 A BRPI0416434 A BR PI0416434A
- Authority
- BR
- Brazil
- Prior art keywords
- asm
- protein
- ceramide
- purified
- activity
- Prior art date
Links
- 229940106189 ceramide Drugs 0.000 title abstract 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title abstract 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title abstract 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 title abstract 3
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000001965 increasing effect Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 150000001783 ceramides Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"MéTODOS PARA AUMENTAR A ATIVIDADE DE UMA PROTEìNA DE áCIDO ESFINGOMIELINASE (ASM), PARA ESTENDER A MEIA-VIDA E PROLONGAR A ATIVIDADE DE UMA PROTEìNA (ASM) PURIFICADA, PARA AUMENTAR A PRODUçãO DE UMA PROTEìNA ASM RECOMBINANTE ATRAVéS DE UMA CéLULA HOSPEDEIRA, E USOS DE UMA COMPOSIçãO DE ASM TIPO ALELO-SELVAGEM, PURIFICADA E UM COMPOSTO ANáLOGO DE CERAMIDA OU ESFINGOMIELINA, E DE UM COMPOSTO ANáLOGO DE CERAMIDA OU DE ESFINGOMIELINA". A presente invenção prove um método para tratar indivíduos afetados pelas formas deficientes de ácido esfingomielinase do mal de Niemann-Pick (ou seja, Niemann-Pick do tipo A e do tipo B), através da administração de pequenas moléculas como 'chaperonas' moleculares específicas, para a deficiência da enzima do ácido esfingomielinase (ASM) associada com a doença. As moléculas são ceramidas, esfingomielina, ou análogos de fosfonucleotídeos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52549703P | 2003-11-25 | 2003-11-25 | |
| PCT/US2004/041345 WO2005051331A2 (en) | 2003-11-25 | 2004-11-24 | Chaperone-based therapy for niemann-pick disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0416434A true BRPI0416434A (pt) | 2007-02-21 |
Family
ID=34632986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416434-2A BRPI0416434A (pt) | 2003-11-25 | 2004-11-24 | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7750050B2 (pt) |
| EP (1) | EP1691819A4 (pt) |
| JP (1) | JP2007514661A (pt) |
| CN (2) | CN101214249A (pt) |
| AU (1) | AU2004293115A1 (pt) |
| BR (1) | BRPI0416434A (pt) |
| CA (1) | CA2546863A1 (pt) |
| IL (1) | IL175749A0 (pt) |
| WO (1) | WO2005051331A2 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009525694A (ja) * | 2006-01-31 | 2009-07-09 | ビシーム コミュニケーションズ インコーポレイテッド | 直交周波数領域変調システムのための変調及び符号化レベル及び空間速度の選択 |
| WO2008128089A1 (en) * | 2007-04-13 | 2008-10-23 | Amicus Therapeutics, Inc. | Use of substrates as pharmacological chaperones |
| PL2318032T3 (pl) | 2008-06-26 | 2012-08-31 | Orphazyme Aps | Zastosowanie hsp70 jako regulatora aktywności enzymatycznej |
| EP2289900A1 (en) | 2009-08-26 | 2011-03-02 | Humboldt Universität zu Berlin | Bisphosphonates as inhibitors of acid sphingomyelinase |
| HRP20211992T1 (hr) | 2009-08-28 | 2022-04-01 | Icahn School Of Medicine At Mount Sinai | Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze |
| US9662375B2 (en) | 2010-11-30 | 2017-05-30 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
| EP2874648A4 (en) | 2012-07-17 | 2015-12-30 | Amicus Therapeutics Inc | CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| TR201906195T4 (tr) * | 2013-05-14 | 2019-05-21 | Centogene Ag | Niemann pıck hastalığının teşhisi için metot. |
| EP3193840B1 (en) | 2014-09-15 | 2021-05-19 | Orphazyme A/S | Arimoclomol formulation |
| WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
| AU2017255959B2 (en) | 2016-04-29 | 2020-10-15 | Zevra Denmark A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| CA3202568A1 (en) | 2020-11-19 | 2022-05-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3255336A (en) * | 1963-02-07 | 1966-06-07 | Hydyn Company | Welding machine |
| US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| US4937232A (en) * | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
| US5244915A (en) * | 1990-08-31 | 1993-09-14 | Warner-Lambert Company | Amico acid derivatives cyclized at the c-terminal |
| US5220043A (en) * | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| US5773278A (en) * | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| US5227508A (en) * | 1992-01-24 | 1993-07-13 | Mayo Foundation For Medical Education And Research | 3-deoxy-3-substituted analogs of phosphatidylinositol |
| US5369030A (en) * | 1992-09-11 | 1994-11-29 | Duke University | Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US5830916A (en) * | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
| WO1999041266A1 (en) * | 1998-02-12 | 1999-08-19 | Emory University | Sphingolipid derivatives and their methods of use |
| US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
| US6756504B2 (en) * | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
| DE60140964D1 (en) | 2001-09-26 | 2010-02-11 | Yissum Res Dev Co | Sphingolipiden |
-
2004
- 2004-11-24 BR BRPI0416434-2A patent/BRPI0416434A/pt not_active Application Discontinuation
- 2004-11-24 US US10/998,270 patent/US7750050B2/en not_active Expired - Fee Related
- 2004-11-24 EP EP04813646A patent/EP1691819A4/en not_active Withdrawn
- 2004-11-24 JP JP2006541513A patent/JP2007514661A/ja active Pending
- 2004-11-24 CN CNA2007101535206A patent/CN101214249A/zh active Pending
- 2004-11-24 WO PCT/US2004/041345 patent/WO2005051331A2/en active Application Filing
- 2004-11-24 CA CA002546863A patent/CA2546863A1/en not_active Abandoned
- 2004-11-24 CN CNA2004800390295A patent/CN1897957A/zh active Pending
- 2004-11-24 AU AU2004293115A patent/AU2004293115A1/en not_active Abandoned
-
2006
- 2006-05-18 IL IL175749A patent/IL175749A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2546863A1 (en) | 2005-06-09 |
| WO2005051331A2 (en) | 2005-06-09 |
| CN101214249A (zh) | 2008-07-09 |
| IL175749A0 (en) | 2008-04-13 |
| CN1897957A (zh) | 2007-01-17 |
| US7750050B2 (en) | 2010-07-06 |
| EP1691819A4 (en) | 2009-05-06 |
| AU2004293115A1 (en) | 2005-06-09 |
| JP2007514661A (ja) | 2007-06-07 |
| EP1691819A2 (en) | 2006-08-23 |
| WO2005051331A3 (en) | 2006-03-02 |
| US20050153934A1 (en) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416434A (pt) | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina | |
| BRPI0507026A (pt) | proteìnas de fusão de albumina | |
| ATE389724T1 (de) | Menschliche dnase i hyperaktive varianten | |
| CY1122128T1 (el) | Θεραπεια ενζυμικης αντικαταστασης με κλιμακωση δοσης για αντιμετωπιση ανεπαρκειας σε οξινη σφιγγομυελιναση | |
| CY1118517T1 (el) | Πνευμονικη χορηγηση για λεβοντοπα | |
| EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| BRPI0413076A (pt) | método analìtico para composições de pancreatina e comparáveis | |
| ATE443720T1 (de) | Fc-interferon-beta fusionsproteine | |
| ECSP088262A (es) | Proteínas de fusión de albúmina | |
| NO20062662L (no) | Muteiner av fibroblast vekstfaktor 21 | |
| BRPI0410041A (pt) | métodos para tratamento de dor de cabeça de sinusite | |
| DE602007009995D1 (de) | Muteine von tearlipocalin und verfahren zu deren gewinnung | |
| BR0009167A (pt) | Inibidores de enzima impdh | |
| DK1673475T3 (da) | Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt | |
| CY1116164T1 (el) | Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου | |
| BR0311205A (pt) | Fosfolipases e seus usos | |
| TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
| BR112012033396A2 (pt) | Polipetídeo tendo atividade swollenin e seus usos. | |
| EA200801077A1 (ru) | Антагонисты взаимодействия pf4 и rantes | |
| BR0308415A (pt) | Métodos de tratamento de diabetes usando-se inibidores de pde11a | |
| BRPI0409793A (pt) | 4-,6- ou 7-hidroxiindóis com grupos n-óxido e sua aplicação como produtos terapêuticos | |
| BR112022019510A2 (pt) | Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher | |
| TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |